Windgap Medical Expands Capacity with Investment in Next-Generation Testing Infrastructure
WATERTOWN, Mass. — June 16, 2026 — Windgap Medical, Inc., a developer of advanced drug delivery devices for complex injectable therapies, today announced an investment in purpose-built testing infrastructure to expand its feasibility and development capacity. The expansion is driven by growing customer demand across Windgap’s portfolio of delivery solutions, including OneMix, MultiMix, and DualFlo.
The new infrastructure investments increase Windgap’s capacity and throughput for customer feasibility and development programs, enabling the company to run more programs in parallel and accelerate the path from early evaluation to a defined development plan. These next generation testing systems are designed to efficiently generate the quantitative performance data that drug developers rely on to make device configuration decisions with confidence.
Windgap has completed a design review on the testing systems, and the build is progressing rapidly. The company expects to complete site acceptance testing (SAT) in early Q3, bringing the added capacity online to support customer programs.
“This investment reflects the strength of our business and a relentless focus on our customer’s needs,” said Aaron Mann, Chief Executive Officer of Windgap Medical. “Demand for OneMix, MultiMix, and DualFlo continues to grow, and expanding our feasibility and development capacity means we can move more customer programs forward, faster, and with the rigor our partners expect.”
The investment underscores Windgap’s commitment to scaling its platform alongside its customers as more drug programs turn to its solutions to enable subcutaneous delivery of reconstituted, combination, and large-volume therapies.
About Windgap Medical
Windgap Medical enables the at-home administration of complex injectable therapies. The company’s three device platforms, built on a shared core architecture, are designed to automate the preparation and delivery of high-viscosity, multi-component, and long-acting formulations. Windgap partners with pharmaceutical innovators at the earliest stages of development, creating the design space needed to bring complex therapies to patients outside of clinical settings. For more information, visit www.windgapmedical.com.
Media Contact: Brent A. Buchine | Email: bbuchine@windgapmedical.com | Phone: (617) 615-6266